ADAKVEO
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$48.6M
Transactions
5,360
Doctors
2,064
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.8M | 94 | 20 |
| 2023 | $6.5M | 129 | 11 |
| 2022 | $14.2M | 1,981 | 1,290 |
| 2021 | $12.0M | 1,211 | 682 |
| 2020 | $8.7M | 987 | 514 |
| 2019 | $3.3M | 956 | 250 |
| 2018 | $43,437 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $47.3M | 802 | 97.3% |
| Consulting Fee | $838,616 | 256 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $222,292 | 94 | 0.5% |
| Travel and Lodging | $124,260 | 358 | 0.3% |
| Food and Beverage | $102,824 | 3,848 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,920 | 2 | 0.0% |
Payments by Type
Research
$47.3M
802 transactions
General
$1.3M
4,558 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER, STUDY TO ASSESS EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB), IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM | Novartis Pharmaceuticals Corporation | $6.4M | 0 |
| A MULTICENTER, ADAPTIVE, RANDOMIZED CONTROLLED PLATFORM TRIAL OF THE SAFETY AND EFFICACY OF ANTITHROMBOTIC STRATEGIES IN HOSPITALIZED ADULTS WITH COVID-19 | Novartis Pharmaceuticals Corporation | $5.6M | 0 |
| A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRIS | Novartis Pharmaceuticals Corporation | $5.2M | 0 |
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PAT | Novartis Pharmaceuticals Corporation | $3.5M | 2 |
| A PHASE II MULTICENTER STUDY TO CONFIRM PK PD OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN ADULT SICKLE CELL DISEASE PATIENTS WITH HISTORY OF VOC | Novartis Pharmaceuticals Corporation | $3.4M | 0 |
| An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study | Novartis Pharmaceuticals Corporation | $3.1M | 0 |
| A PILOT STUDY OF CRIZANLIZUMAB FOR THE TREATMENT OF RETINAL VASCULOPATHY WITH CEREBRAL LEUKOENCEPHALOPATHY (RVCL) | Novartis Pharmaceuticals Corporation | $3.1M | 0 |
| A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises | Novartis Pharmaceuticals Corporation | $3.1M | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PATIENTS WITH VASO-OCCLUSIVE CRISES | Novartis Pharmaceuticals Corporation | $2.8M | 2 |
| A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRISIS | Novartis Pharmaceuticals Corporation | $2.7M | 0 |
| A PHASE II, MULTICENTER, RANDOMIZED, OPEN LABEL TWO ARM STUDY COMPARING THE EFFECT OF CRIZANLIZUMAB + STANDARD OF CARE TO STANDARD OF CARE ALONE ON RENAL FUNCTION IN SICKLE CELL DISEASE PATIENTS >/= 16 YEARS WITH CHRONIC KIDNEY DISEASE DUE TO SICKLE CE | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| A PHASE II, MULTICENTER, RANDOMIZED, OPEN LABEL TWO ARM STUDY COMPARING THE EFFECT OF CRIZANLIZUMAB + STANDARD OF CARE TO STANDARD OF CARE ALONE ON RENAL FUNCTION IN SICKLE CELL DISEASE PATIENTS >/= 16 YEARS WITH CHRONIC KIDNEY DISEASE DUE TO SICKLE CELL NEPHROPATHY | Novartis Pharmaceuticals Corporation | $989,047 | 0 |
| A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (crizanlizumab), in Sickle Cell Disease Patients with Priapism | Novartis Pharmaceuticals Corporation | $815,838 | 0 |
| AN OPEN-LABEL, MULTI-CENTER, PHASE IV, ROLLOVER STUDY FOR PATIENTS WITH SICKLE CELL DISEASE WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED CRIZANLIZUMAB STUDY | Novartis Pharmaceuticals Corporation | $730,059 | 0 |
| A phase II Multicenter Study to Confirm PK PD of crizanlizumab with or without Hydroxyurea Hydroxycarbamide in Adult Sickle Cell Disease Patients with history of VOC | Novartis Pharmaceuticals Corporation | $650,875 | 0 |
| A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or without Hydroxyurea Hydroxycarbamide in Sequential Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso Occlusive Crisis | Novartis Pharmaceuticals Corporation | $632,230 | 0 |
| An exploratory biomarker investigation of crizanlizumab in sickle cell disease patients exploring the proteome, red blood cell rheology, neutrophil extracellular traps and platelet function | Novartis Pharmaceuticals Corporation | $533,939 | 0 |
| TARGETING VASCULAR INFLAMMATION IN MODERATE COVID-19 WITH CRIZANLIZUMAB: A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL | Novartis Pharmaceuticals Corporation | $530,356 | 0 |
| A Pilot Study of Crizanlizumab for the Treatment of Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL) | Novartis Pharmaceuticals Corporation | $485,730 | 0 |
| Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in Sickle Cell Anemia | Novartis Pharmaceuticals Corporation | $448,189 | 0 |
Top Doctors Receiving Payments for ADAKVEO — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Blood Banking & Transfusion Medicine | Saint Louis, MO | $9,607 | 9 |
| , DO | Pediatric Hematology-Oncology | Birmingham, AL | $9,588 | 29 |
| , MD | Hematology & Oncology | Vallejo, CA | $9,421 | 10 |
| , MD | Pediatric Hematology-Oncology | Cleveland, OH | $9,394 | 11 |
| , MD | Internal Medicine | Richmond, VA | $8,962 | 7 |
| , M.D | Pediatric Hematology-Oncology | Brooklyn, NY | $8,504 | 9 |
| , DO | Pediatric Hematology-Oncology | Charleston, SC | $8,208 | 5 |
| , M.D | Pediatric Hematology-Oncology | Bethesda, MD | $8,108 | 11 |
| , MD | Medical Oncology | Southfield, MI | $8,020 | 3 |
| , M.D | Emergency Medicine | Brooklyn, NY | $7,522 | 5 |
| Cheryl Harth | — | Dallas, TX | $7,369 | 6 |
| , MD | Pediatric Hematology-Oncology | Mangonia Park, FL | $7,158 | 6 |
| , M.D | Hematology & Oncology | Fort Lauderdale, FL | $7,124 | 6 |
| , M.D | Emergency Medicine | Brooklyn, NY | $7,049 | 5 |
| , MD, FACP | Medical Oncology | Beaumont, TX | $7,005 | 5 |
| , MD | Hematology | Columbus, OH | $6,855 | 5 |
| , MD | Internal Medicine | Tampa, FL | $6,778 | 4 |
| , DO | Internal Medicine | Charlotte, NC | $6,712 | 10 |
| , M.D | Hematology & Oncology | Atlanta, GA | $6,663 | 3 |
| , M.D | Hematology | Houston, TX | $6,660 | 18 |
| , MD | Emergency Medicine | Brooklyn, NY | $6,468 | 5 |
| , MD | Pediatric Hematology-Oncology | Oakland, CA | $6,411 | 5 |
| , D.O | Internal Medicine | Brooklyn, NY | $6,359 | 5 |
| , MD | Obesity Medicine | Tampa, FL | $6,179 | 35 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $5,724 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $48.2M
- NOVARTIS PHARMACEUTICALS CORPORATION $351,216
- Novartis Pharma AG $75,015
Product Information
- Type Biological
- Total Payments $48.6M
- Total Doctors 2,064
- Transactions 5,360
About ADAKVEO
ADAKVEO is a biological associated with $48.6M in payments to 2,064 healthcare providers, recorded across 5,360 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2024. In 2024, $3.8M was paid across 94 transactions to 20 doctors.
The most common payment nature for ADAKVEO is "Unspecified" ($47.3M, 97.3% of total).
ADAKVEO is associated with 20 research studies, including "A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER, STUDY TO ASSESS EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB), IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM" ($6.4M).